Literature DB >> 17119118

Arginase 1 is expressed in myelocytes/metamyelocytes and localized in gelatinase granules of human neutrophils.

Lars C Jacobsen1, Kim Theilgaard-Mönch, Erik I Christensen, Niels Borregaard.   

Abstract

Arginase 1 (ARG1) metabolizes arginine, thus reducing the availability of arginine as a substrate for nitric oxide synthase (NOS). The decreased production of nitric oxide (NO) by NOS and the production of ornithine by ARG1 affect immune responses and tissue regeneration at sites of infection, respectively. We here demonstrate that ARG1 is synthesized in myelocytes/metamyelocytes and is stored in gelatinase granules. In accordance with this, activated neutrophils coreleased ARG1 and gelatinase to the extracellular environment on stimulation with phorbol-12-myristate 13-acetate (PMA), formyl-methionyl-leucyl-phenylalanine (fMLP), or tumor necrosis factor alpha (TNF-alpha). Overall, these findings define ARG1 as a genuine gelatinase granule protein and support a model in which activated neutrophils release ARG1 at sites of infection to modulate immune responses and promote tissue regeneration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17119118     DOI: 10.1182/blood-2006-06-032599

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  Arginase I levels are decreased in the plasma of pediatric patients with atopic dermatitis.

Authors:  Victoria Dimitriades; Paulo C Rodriguez; Jovanny Zabaleta; Augusto C Ochoa
Journal:  Ann Allergy Asthma Immunol       Date:  2014-07-11       Impact factor: 6.347

Review 2.  The Ontogeny of a Neutrophil: Mechanisms of Granulopoiesis and Homeostasis.

Authors:  Shelley M Lawrence; Ross Corriden; Victor Nizet
Journal:  Microbiol Mol Biol Rev       Date:  2018-02-07       Impact factor: 11.056

3.  Role of arginase 1 from myeloid cells in th2-dominated lung inflammation.

Authors:  Luke Barron; Amber M Smith; Karim C El Kasmi; Joseph E Qualls; Xiaozhu Huang; Allen Cheever; Lee A Borthwick; Mark S Wilson; Peter J Murray; Thomas A Wynn
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

4.  Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.

Authors:  Selvakumar Subbian; Liana Tsenova; Paul O'Brien; Guibin Yang; Mi-Sun Koo; Blas Peixoto; Dorothy Fallows; Jerome B Zeldis; George Muller; Gilla Kaplan
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

5.  Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1.

Authors:  Sarah A Ingersoll; Julie Laval; Osric A Forrest; Marcela Preininger; Milton R Brown; Dalia Arafat; Greg Gibson; Vin Tangpricha; Rabindra Tirouvanziam
Journal:  J Immunol       Date:  2015-04-29       Impact factor: 5.422

6.  The pattern of GPI-80 expression is a useful marker for unusual myeloid maturation in peripheral blood.

Authors:  Y Takeda; T Kato; H Ito; Y Kurota; A Yamagishi; T Sakurai; A Araki; H Nara; N Tsuchiya; H Asao
Journal:  Clin Exp Immunol       Date:  2016-10-04       Impact factor: 4.330

7.  Roles of arginase variants, atopy, and ozone in childhood asthma.

Authors:  Muhammad T Salam; Talat Islam; W James Gauderman; Frank D Gilliland
Journal:  J Allergy Clin Immunol       Date:  2009-03       Impact factor: 10.793

Review 8.  Arginase: an emerging key player in the mammalian immune system.

Authors:  Markus Munder
Journal:  Br J Pharmacol       Date:  2009-09-17       Impact factor: 8.739

9.  Induction of human IL-10-producing neutrophils by LPS-stimulated Treg cells and IL-10.

Authors:  N Lewkowicz; M P Mycko; P Przygodzka; H Ćwiklińska; M Cichalewska; M Matysiak; K Selmaj; P Lewkowicz
Journal:  Mucosal Immunol       Date:  2015-07-29       Impact factor: 7.313

Review 10.  Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.

Authors:  Paulo C Rodríguez; Augusto C Ochoa
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.